Skip Page Header

Home > Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances. Risk Assessments.

European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances. Risk Assessments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.

[img]
Preview
PDF (Risk assessment AB-CHMINACA) - Published Version
830kB

This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.


Item Type
Report
Publication Type
International, Guideline, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Date
2018
Pages
67 p.
Publisher
European Monitoring Centre for Drugs and Drug Addiction
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page